Application of small molecule compound YK-4-279 in preparation of medicine for treating hepatitis B
By combining the small molecule compound YK-4-279 with entecavir, the transcription and expression of APOBEC3C is promoted, and the problem of limited therapeutic effect of HBV in the prior art is solved, significantly inhibiting HBV replication and enhancing the therapeutic effect.
Patent Information
- Application Number
- CN202411139544.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-22
AI Technical Summary
The existing hepatitis B treatment drugs have limited effect on HBV. Nucleoside analog drugs require long-term medication and may lead to drug resistance mutations. Interferon treatment has great side effects and limited efficacy.
The small molecule compound YK-4-279 was used in combination with entecavir. YK-4-279 inhibited HBV replication by promoting transcription and expression of APOBEC3C and used in combination with existing drugs to enhance antiviral effects.
YK-4-279 significantly inhibits HBV replication, reduces the levels of HBV core DNA, HBsAg and HBc, reduces the dosage of entecavir, enhances the therapeutic effect, and has broad application prospects in the development of new drugs and scientific research and detection of HBV diseases.
Smart Images

Figure CN118986970A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedicine, and specifically relates to the application of a small molecule compound YK-4-279 in the preparation of a drug for treating hepatitis B. Background Art
[0002] Hepatitis B virus (HBV) infection is a serious public health problem. Currently, about 257 million people worldwide are chronically infected with HBV. Chronic HBV infection can lead to chronic hepatitis B (CHB) and progress to cirrhosis and hepatocellular carcinoma. HBV is a hepatotropic DNA virus with a genome of approximately 3.2 kb. It replicates in a unique reverse transcription mode. HBV enters hepatocytes through the preS1 region of hepatitis B surface antigen (HBsAg) binding to sodium-taurocholate cotransporting polypeptide (NTCP) on the surface of hepatocytes. After HBV enters hepatocytes, it releases its nucleocapsid to form relaxed circular DNA (rcDNA). rcDNA enters the cell nucleus to form covalently closed circular DNA (cccDNA). cccDNA exists in hepatocytes in the form of minichromosomes and is a template for the transcription of four HBV mRNAs and the translation of seven viral proteins. Among them, the 3.5kb pregenomic RNA (pgRNA) can encode hepatitis B virus core antigen (HBc), hepatitis B virus e antigen (HBeAg) and DNA polymerase, and participate in the reverse transcription and replication process of HBV. During HBV replication, HBV DNA polymerase binds to the 5'-stem-loop structure (ε-stem-loop) of pgRNA to initiate core antigen assembly. In the nucleocapsid, pgRNA is reversely transcribed to form negative strand (-) DNA, followed by positive strand (+) DNA, and then to form daughter rcDNA. On the one hand, rcDNA can be recycled into the cell nucleus to form cccDNA and maintain the cccDNA pool. On the other hand, rcDNA completes envelope protein packaging and maturation, and is finally secreted outside the cell.
[0003] The drugs currently used to treat CHB mainly include nucleoside analogues (NAs) such as entecavir (ETV) and tenofovir disoproxil fumarate, and interferon drugs such as pegylated interferon-α. These drugs can inhibit HBV replication and reduce liver inflammation, thereby delaying or reducing the incidence of liver failure, hepatocellular carcinoma and other complications. However, NAs require long-term medication, but long-term use of NAs may cause the virus to produce drug-resistant mutations, which reduces the efficacy of the drug; interferon treatment has large side effects, and only a few patients can achieve sustained virological responses. Therefore, the currently commonly used NAs and interferons have limited therapeutic effects on HBV. Summary of the invention
[0004] In view of this, the purpose of the present invention is to provide the use of the small molecule compound YK-4-279 in the preparation of hepatitis B therapeutic drugs, which can alleviate or partially alleviate the deficiencies of the prior art. The specific technical scheme is as follows.
[0005] The use of YK-4-279 in the preparation of a drug for treating HBV infection, wherein the chemical structure of YK-4-279 is as follows:
[0006] Application of YK-4-279 in the preparation of medicines for treating hepatitis B.
[0007] Furthermore, the drug also includes other pharmaceutically acceptable carriers and / or adjuvants.
[0008] The application of YK-4-279 in the preparation of a reagent for inhibiting HBV replication has a prospect for scientific research application.
[0009] The application of YK-4-279 and entecavir in the preparation of drugs for treating HBV infection.
[0010] Furthermore, the dosage concentration range of the YK-4-279 and the entecavir when used in combination is YK-4-279:entecavir equal to 5-10:1.
[0011] Preferably, the dosage concentration range of the YK-4-279 and entecavir when used in combination is YK-4-279: entecavir equal to 10:1.
[0012] A reagent is used in the preparation of a drug efficacy evaluation product, wherein the product is used to evaluate the inhibitory effect of YK-4-279 on HBV replication; the reagent includes a hepatitis B virus surface antigen detection reagent, an HBV core DNA detection reagent or a 3.5kb HBV RNA detection reagent.
[0013] Furthermore, the drug efficacy evaluation product includes YK-4-279 and experimental cells independently configured in unit doses.
[0014] Further, when YK-4-279 has an inhibitory effect on HBV replication, the hepatitis B virus surface antigen, HBVcore DNA level and / or 3.5kb HBV RNA level decrease.
[0015] As an option, the HBV core DNA detection reagent comprises a set of primer pairs, and the sequences of the primer pairs are shown as SEQ ID NO.1 and SEQ ID NO.2.
[0016] As an option, the 3.5kb HBV RNA detection reagent comprises a set of primer pairs, and the sequences of the primer pairs are shown in SEQ ID NO.3 and SEQ ID NO.4.
[0017] The primer sequences involved above are shown in the table below.
[0018] Table 1 NO. sequence 1 TGCGGCGTTTTATCATATTCC 2 ATACCTTGGTAGTCCAGAAGAACCA 3 CCTAGTAGTCAGTTATGTCAAC 4 TCTATAAGCTGGAGGAGTGCGA
[0019] Beneficial technical effects
[0020] The present invention proposes a small molecule compound YK-4-279 for inhibiting HBV infection, the molecular formula of which is C 17 H 13 C l2 NO4 belongs to the indolinone class of compounds, and (S)-YK-4-279 is its active form. At present, YK-4-279 is mainly used in the anti-tumor field, and the antiviral effect of YK-4-279 has not been reported. The experiment of the present invention confirmed that YK-4-279 can significantly inhibit HBV replication, and it was found that this inhibitory effect depends on promoting the transcription and expression of APOBEC3C. APOBEC3C can interact with HBc, be packaged into viral particles, edit the negative-strand (-) DNA in the process of HBV reverse transcription and replication, deaminize cytosine to form uracil, and inhibit HBV replication.
[0021] Cell model experiments have confirmed that YK-4-279 can reduce the levels of HBV core DNA, HBsAg, and HBc; and YK-4-279 promotes APOBEC3C transcription and expression, inhibiting HBV replication. In addition, YK-4-279 significantly enhances the effect of inhibiting HBV replication when used in combination with ETV, and can also reduce the amount of ETV used. It has broad application prospects in the development of new drugs for hepatitis B disease and in scientific research reagents and detection. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the prior art descriptions are briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention, and for ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor.
[0023] Figure 1 The results of the cytotoxicity test of YK-4-279 on HepAD38 and HepG2-NTCP cells;
[0024] Figure 2 The results show that YK-4-279 inhibits HBsAg secretion, HBV coreDNA level, 3.5kb HBV RNA level and HBc level in the HepAD38 cell model of HBV replication.
[0025] Figure 3 The results show that YK-4-279 inhibits HBsAg secretion, HBV core DNA level, 3.5kb HBV RNA level, and HBc level in the HBV-infected HepG2-NTCP cell model.
[0026] Figure 4 This is the test result of the antiviral effect of YK-4-279 combined with ETV;
[0027] Figure 5 YK-4-279 promotes the transcription and expression of APOBEC3C. DETAILED DESCRIPTION
[0028] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0029] Herein "and / or" includes any and all combinations of one or more of the associated listed items.
[0030] Herein, "plurality" means two or more than two, ie, it includes two, three, four, five, etc.
[0031] It should be noted that, in this article, the terms "include", "comprises" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device. In the absence of further restrictions, an element defined by the sentence "comprises a ..." does not exclude the existence of other identical elements in the process, method, article or device including the element.
[0032] As used in this specification, the term "about" typically means + / - 5% of the stated value, more typically + / - 4% of the stated value, more typically + / - 3% of the stated value, more typically + / - 2% of the stated value, even more typically + / - 1% of the stated value, and even more typically + / - 0.5% of the stated value.
[0033] In this specification, some embodiments may be disclosed in a format of being within a certain range. It should be understood that such description of "being within a certain range" is only for convenience and brevity, and should not be interpreted as a rigid limitation on the disclosed range. Therefore, the description of the range should be considered to have specifically disclosed all possible sub-ranges and independent numerical values within this range. For example, the range The description of should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within this range, for example, 1, 2, 3, 4, 5, and 6. The above rules apply regardless of the breadth of the range.
[0034] Experimental Materials:
[0035] YK-4-279, tetracycline, and ETV were purchased from MedChemExpress, USA; fetal bovine serum, DMEM, penicillin-streptomycin solution, and trypsin were purchased from Shanghai Yuanpei Company; APOBEC3C antibody was purchased from Beijing Solebao Company; Opti-MEM, Williams' Medium, and L-Glutamine were purchased from Gibco, USA
[0036] Cell culture:
[0037] The following examples use two cell lines: human liver cancer HepAD38 and HepG2-NTCP cells. The cells were cultured in DMEM medium (hereinafter referred to as cell culture medium) containing 10% fetal bovine serum, 100U / mL penicillin and 100μg / mL streptomycin under 5% CO2 and 37°C; 1μg / ml tetracycline was additionally added to HepAD38 to inhibit HBV pgRNA transcription.
[0038] Example 1
[0039] In this example, the cytotoxicity of YK-4-279 in HepAD38 and HepG2-NTCP cells was detected by MTT assay.
[0040] Experimental method: HepAD38 and HepG2-NTCP cells with good growth status were cultured at 5×10 3 Cells / well were inoculated in a 96-well plate, and different concentrations of YK-4-279 (3 concentrations: 0, 50, 100 nmol / L) were added. Five replicate wells were set for each concentration group. Negative control wells and blank wells were also set. The plates were placed in an incubator and treated with drugs for 48 hours. The culture plates were removed, the supernatant was discarded, and fresh culture medium and 10 μl MTT reagent were added to each well and mixed. The plates were cultured in an incubator for 1 hour. 100 μl formazan was added to each well, shaken for 10 minutes, and the absorbance was detected at a wavelength of 570 nm. The logarithm of the drug concentration was used as the horizontal axis and the cell activity was used as the vertical axis. The fitting curve was prepared using GraphPad prism 9 software to detect the half cytotoxic concentration CC. 50 .
[0041] Experimental results: see Figure 1 The half cytotoxic concentration CC of YK-4-279 on HepAD38 cells and HepG2-NTCP cells 50 They were 6.0 μmol / L and 5.3 μmol / L respectively.
[0042] Example 2
[0043] 2.1 Detection of the antiviral effect of YK-4-279 in HBV-replicating HepAD38 cells.
[0044] Well-growing HepAD38 and HepG2-NTCP cells were cultured at 3×10 5 Cells / well were inoculated in a 6-well plate, and cell culture medium containing 50nmol / L and 100nmol / L of YK-4-279 was added and cultured for 48h. A DMSO negative control group was set up. After 48h of culture, HBsAg (Hepatitis B virus surface antigen diagnostic kit, Shanghai Kehua) and HBeAg (Hepatitis B virus surface antigen diagnostic kit, Shanghai Kehua) in the cell supernatant were detected. The operation method was carried out according to the instructions of the kit. In addition, the HBc expression level, HBV core DNA, and 3.5kb HBV RNA levels were also detected.
[0045] Extraction of intracellular HBV core DNA:
[0046] After cell lysis, centrifugation was performed, and the exogenous genome was digested with micrococcal nuclease in the supernatant. The DNA was then precipitated with PEG 8 000, digested with proteinase K, and the DNA was extracted with phenol: chloroform: isoamyl alcohol = 25:24:1. Finally, HBVcore DNA was obtained by ethanol purification.
[0047] Quantitative PCR (qPCR) detection of viral particle DNA:
[0048] Use gradient dilution of HBV expression plasmid to prepare standards with different concentration gradients. Prepare qPCR reaction system, where the primer sequences are HBV DNA forward 5'-TGCGGCGTTTTATCATATTCC-3', HBV DNA reverse 5'-ATACCTTGGTAGTCCAGAAGAACCA-3'. qPCR amplify standards and samples. Draw a standard curve based on the results of the standard, bring the CT value of the sample into the standard curve, and calculate the content of HBV core DNA.
[0049] Detection of 3.5kb HBV RNA in cells:
[0050] Total RNA was extracted from cells using the Trizol method (TIANGEN), and the purity and concentration of RNA were detected using a spectrophotometer (Thermo Fisher Scientific, USA). RNA was reverse transcribed into cDNA using a reverse transcription kit (Thermo Fisher Scientific, USA). Standards with different concentration gradients were prepared. A qPCR reaction system was prepared, in which the primer sequences were 3.5kb HBV RNAforward 5'-CCTAGTAGTCAGTTATGTCAAC-3' and 3.5kb HBV RNAreverse 5'-TCTATAAGCTGGAGGAGTGCGA-3'. Standards and samples were amplified by qPCR. A standard curve was drawn based on the results of the standard, and the CT value of the sample was brought into the standard curve to calculate the 3.5kb HBV RNA content.
[0051] The detection method of intracellular HBc is the same as the protein detection of APOBEC3C.
[0052] Experimental results: see Figure 2 YK-4-279 dose-dependently inhibited the secretion of HBsAg in the supernatant and suppressed the levels of HBc, HBVcore DNA, and 3.5kb HBV RNA.
[0053] 2.2 Antiviral effect of YK-4-279 in HBV-infected HepG2-NTCP cell model.
[0054] Method for constructing an in vitro HBV infection cell model using HepG2-NTCP cells:
[0055] The supernatant of cultured HepAD38 cells was collected and centrifuged to remove cell debris. HBV virus particles were precipitated by PEG 8 000 method and dissolved in Opti-MEM. DNA was extracted and the copy number of concentrated virus was detected by qPCR. 1×10 5 HepG2-NTCP cells were cultured in vitro; one day before infection, the cells were replaced with infection medium. HepG2-NTCP cells were infected with 1 000 viral gene equivalents / cell; 24 hours after infection, the cells were washed three times with phosphate buffer and replaced with cell culture medium containing different concentrations of YK-4-279 for 48 hours. After 48 hours, the levels of HBsAg and HBeAg, cellular HBV core DNA, 3.5kb HBV RNA, and HBc in the supernatant were detected. The method was the same as above.
[0056] Experimental results: see Figure 3 YK-4-279 dose-dependently inhibited the secretion of HBsAg in the supernatant and suppressed the levels of HBc, HBV coreDNA, and 3.5kb HBV RNA.
[0057] Example 3
[0058] Evaluation of the antiviral effect of YK-4-279 combined with ETV.
[0059] Well-growing HepAD38 cells and HepG2-NTCP cells were cultured at 3×10 5 Cells / well were seeded in 6-well plates, and DMSO control group, YK-4-279 treatment group, ETV treatment group and combined treatment group were set up. The final concentration of YK-4-279 was 100nmol / L YK-4-279 in the YK-4-279 treatment group; the final concentration of ETV in the ETV treatment group was 10nmol / L ETV; the final concentration of YK-4-279 and 10nmol / L ETV in the combined treatment group was 100nmol / L. After 48h, HBV core DNA levels were detected in HepAD38 and HepG2-NTCP cell models, respectively.
[0060] Experimental results: see Figure 4 Compared with the YK-4-279 and ETV single treatment groups, the YK-4-279 and ETV combined treatment group significantly reduced the HBV core DNA level, proving that YK-4-279 enhanced the antiviral effect of ETV.
[0061] The known literature reports that the ETV treatment concentration is 25nmol / L, at which ETV significantly inhibits HBV replication. In this embodiment, the ETV treatment concentration is reduced to 10nmol / L, at which the inhibition rate of ETV on HBV replication is about 50%, and after further combining with YK-4-279, HBV replication is further inhibited. Therefore, YK-4-279 combined with ETV can significantly inhibit HBV replication.
[0062] Example 4
[0063] Detect the upregulation effect of YK-4-279 on APOBEC3C.
[0064] Well-growing HepAD38 and HepG2-NTCP cells were cultured at 3×10 5 10 cells / well were seeded in a 6-well plate and treated with cell culture medium containing different concentrations of YK-4-279 (3 concentrations: 0, 50, 100 nmol / L) for 48 h. Total RNA was then extracted using the Trizol method (TIANGEN), and the purity and concentration of RNA were detected using a spectrophotometer (Thermo Fisher Scientific, USA). A 260 / A 280 The concentration was adjusted between 1.80-2.00 and 500-1000 ng / μL. The RNA was reverse transcribed into cDNA using a reverse transcription kit (Thermo Fisher Scientific, USA). GAPDH was used as the internal reference gene, and the primer sequences were GAPDH forward 5'-GAAGGTGAAGGTCGGAGTC-3', GAPDH reverse 5'-GAAGATGGTGATGGGATTTC-3'; the primer sequences for APOBEC3C were APOBEC3C forward 5'-TCAGAAACCCGATGAAGG-3', APOBEC3Creverse 5'-GGTGAAGCACAGCCAAGT-3'. PCR amplification of standards and samples was performed, and the results were analyzed using 2 -ΔΔct Methods The relative amount of APOBEC3C mRNA was calculated.
[0065] Total protein was extracted using RIPA reagent (Sanggong, China), and protein concentration was detected using BCA method (Sanggong, China). Proteins were separated by SDS-PAGE, transferred to PVDF membrane, blocked with 5% skim milk powder, and incubated with APOBEC3C (Solaibao, China) antibody at 4°C overnight. Then, secondary antibody (Biosharp, China) was incubated at room temperature for 1 hour. Appropriate amount of ECL reagent (MedChemExpress, USA) was added for imaging in an imager.
[0066] Experimental results: see Figure 5 , YK-4-279 upregulated the mRNA of APOBEC3C and effectively increased the protein expression level of APOBEC3C.
[0067] The embodiments of the present invention are described above in conjunction with the accompanying drawings, but the present invention is not limited to the above-mentioned specific implementation modes, which are merely illustrative rather than restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the present invention and the claims, all of which are within the protection of the present invention.
Claims
1. Use of YK-4-279 in the preparation of drugs for treating hepatitis B virus infection, It is characterized in that The chemical structural formula of the YK-4-279 is as follows:
2. Application of YK-4-279 in the preparation of drugs for treating hepatitis B, It is characterized in that The chemical structural formula of the YK-4-279 is as follows:
3. The use according to claim 1 or 2, It is characterized in that The medicine also includes other pharmaceutically acceptable carriers and / or adjuvants.
4. Application of YK-4-279 in the preparation of reagents for inhibiting hepatitis B virus replication, It is characterized in that The chemical structural formula of the YK-4-279 is as follows:
5. Use of YK-4-279 and entecavir in combination for the preparation of a drug for treating hepatitis B virus infection, It is characterized in that The chemical structural formula of the YK-4-279 is as follows:
6. The use according to claim 5, It is characterized in that The dosage concentration range of the YK-4-279 and the entecavir when used in combination is YK-4-279:entecavir equals 5-10:
1.
7. The use according to claim 6, It is characterized in that The dosage concentration range of the YK-4-279 and the entecavir when used in combination is YK-4-279:entecavir equals 10:
1.
8. Use of a reagent in the preparation of a drug efficacy evaluation product, It is characterized in that The product is used to evaluate the inhibitory effect of YK-4-279 on the replication of hepatitis B virus; the reagents include hepatitis B virus surface antigen detection reagent, HBVcore DNA detection reagent and / or 3.5kb HBV RNA detection reagent; the chemical structure of YK-4-279 is as follows:
9. The use according to claim 8, It is characterized in that The drug efficacy evaluation product includes YK-4-279 and experimental cells independently configured in unit doses.
10. The use according to claim 8, It is characterized in that When YK-4-279 has an inhibitory effect on the replication of hepatitis B virus, the hepatitis B virus surface antigen, HBV coreDNA level and / or 3.5kb HBV RNA level decrease.
